Silenseed Announces FDA Orphan Designation of siG12D-LODER Drug/Treatment. logo1c

Jerusalem, January 26 2015 - Silenseed LTD announces the receipt of Orphan Drug designation from the FDA's Office of Orphan Products Development for siG12D-LODER for treatment of pancreatic cancer.

 "The Orphan Drug designation of siG12D-LODER for the treatment of pancreatic cancer is Silenseed's first RNAi-based treatment regulatory submission" said Dr. Amotz Shemi, CEO of Silenseed. "We’ve completed a successful Phase 1/2a trial in patients with locally advanced pancreatic cancer (LAPC). The results of the trial showed that siG12D-LODER is safe and well tolerated. Moreover, there were clear early evidences of an extended overall survival rate, the halting of tumor growth in all patients, and in most cases shrinkage of the tumor. With these encouraging outcomes we are preparing our multinational, randomized and controlled Phase 2/3 trial in LPAC, expected to start later this year (NCT01676259)"

FDA's official Orphan Drug Designation and Approval


Silenseed to Present at Biotech Showcase 2015bioshowcase

Silenseed LTD, will present at Biotech Showcase 2015 on Wednesday January 14, 2015 at 4:45pm PST. The investor and partnering conference will take place at the Parc 55 Wyndham San Francisco- Union Square.
Silenseed's Chief Executive Officer, Amotz Shemi, PhD, will provide a corporate overview including recent advancements of the Company’s successful Phase 1/2a clinical trial evaluating siG12D-LODER™ in patients with locally advanced pancreatic cancer, and the preparation toward Phase 2b.

Members of the investment community and attendees may also request one-on-one meetings with Dr. Shemi at the conference by contacting

Read More


Inside Silenseed